Literature DB >> 25486872

miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.

D Guinn1, A S Ruppert2, K Maddocks2, S Jaglowski2, A Gordon2, T S Lin3, R Larson4, G Marcucci2, E Hertlein2, J Woyach2, A J Johnson5, J C Byrd5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25486872      PMCID： PMC4424166          DOI： 10.1038/leu.2014.344

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  16 in total

1.  Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

Authors:  Sarah E M Herman; Amber L Gordon; Erin Hertlein; Asha Ramanunni; Xiaoli Zhang; Samantha Jaglowski; Joseph Flynn; Jeffrey Jones; Kristie A Blum; Joseph J Buggy; Ahmed Hamdy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

2.  Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.

Authors:  Jennifer A Woyach; Kelly Smucker; Lisa L Smith; Arletta Lozanski; Yiming Zhong; Amy S Ruppert; David Lucas; Katie Williams; Weiqiang Zhao; Laura Rassenti; Emanuela Ghia; Thomas J Kipps; Rose Mantel; Jeffrey Jones; Joseph Flynn; Kami Maddocks; Susan O'Brien; Richard R Furman; Danelle F James; Fong Clow; Gerard Lozanski; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2014-01-10       Impact factor: 22.113

3.  Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).

Authors:  Jennifer A Woyach; Engin Bojnik; Amy S Ruppert; Matthew R Stefanovski; Virginia M Goettl; Kelly A Smucker; Lisa L Smith; Jason A Dubovsky; William H Towns; Jessica MacMurray; Bonnie K Harrington; Melanie E Davis; Stefania Gobessi; Luca Laurenti; Betty Y Chang; Joseph J Buggy; Dimitar G Efremov; John C Byrd; Amy J Johnson
Journal:  Blood       Date:  2013-12-05       Impact factor: 22.113

4.  ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.

Authors:  Adrian Wiestner; Andreas Rosenwald; Todd S Barry; George Wright; R Eric Davis; Sarah E Henrickson; Hong Zhao; Rachel E Ibbotson; Jenny A Orchard; Zadie Davis; Maryalice Stetler-Stevenson; Mark Raffeld; Diane C Arthur; Gerald E Marti; Wyndham H Wilson; Terry J Hamblin; David G Oscier; Louis M Staudt
Journal:  Blood       Date:  2003-02-20       Impact factor: 22.113

Review 5.  Regulation of the MIR155 host gene in physiological and pathological processes.

Authors:  Terry S Elton; Helina Selemon; Shane M Elton; Narasimham L Parinandi
Journal:  Gene       Date:  2012-12-14       Impact factor: 3.688

Review 6.  MicroRNAs and B cell receptor signaling in chronic lymphocytic leukemia.

Authors:  Marek Mraz; Thomas J Kipps
Journal:  Leuk Lymphoma       Date:  2013-06-12

7.  MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia.

Authors:  Bing Cui; Liguang Chen; Suping Zhang; Marek Mraz; Jessie-F Fecteau; Jian Yu; Emanuela M Ghia; Ling Zhang; Lei Bao; Laura Z Rassenti; Karen Messer; George A Calin; Carlo M Croce; Thomas J Kipps
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

8.  Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

Authors:  John C Byrd; Bercedis L Peterson; Vicki A Morrison; Kathleen Park; Robert Jacobson; Eva Hoke; James W Vardiman; Kanti Rai; Charles A Schiffer; Richard A Larson
Journal:  Blood       Date:  2002-07-05       Impact factor: 22.113

9.  LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas.

Authors:  Yong Zhang; Aldo M Roccaro; Christopher Rombaoa; Ludmilla Flores; Susanna Obad; Stacey M Fernandes; Antonio Sacco; Yang Liu; Hai Ngo; Phong Quang; Abdel Kareem Azab; Feda Azab; Patricia Maiso; Michaela Reagan; Jennifer R Brown; To-Ha Thai; Sakari Kauppinen; Irene M Ghobrial
Journal:  Blood       Date:  2012-07-13       Impact factor: 22.113

10.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245
View more
  10 in total

1.  BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor.

Authors:  Hatice Gulcin Ozer; Dalia El-Gamal; Ben Powell; Gideon Bollag; John C Byrd; Rosa Lapalombella; Zachary A Hing; James S Blachly; Bonnie Harrington; Shaneice Mitchell; Nicole R Grieselhuber; Katie Williams; Tzung-Huei Lai; Lapo Alinari; Robert A Baiocchi; Lindsey Brinton; Elizabeth Baskin; Matthew Cannon; Larry Beaver; Virginia M Goettl; David M Lucas; Jennifer A Woyach; Deepa Sampath; Amy M Lehman; Lianbo Yu; Jiazhong Zhang; Yan Ma; Ying Zhang; Wayne Spevak; Songyuan Shi; Paul Severson; Rafe Shellooe; Heidi Carias; Garson Tsang; Ken Dong; Todd Ewing; Adhirai Marimuthu; Christina Tantoy; Jason Walters; Laura Sanftner; Hamid Rezaei; Marika Nespi; Bernice Matusow; Gaston Habets; Prabha Ibrahim; Chao Zhang; Ewy A Mathé
Journal:  Cancer Discov       Date:  2018-01-31       Impact factor: 39.397

Review 2.  Clinical significance of microRNAs in chronic and acute human leukemia.

Authors:  Chien-Hung Yeh; Ramona Moles; Christophe Nicot
Journal:  Mol Cancer       Date:  2016-05-14       Impact factor: 27.401

3.  MicroRNA-491 regulates the proliferation and apoptosis of CD8(+) T cells.

Authors:  Ting Yu; Qian-Fei Zuo; Li Gong; Li-Na Wang; Quan-Ming Zou; Bin Xiao
Journal:  Sci Rep       Date:  2016-08-03       Impact factor: 4.379

4.  The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia.

Authors:  Cecelia R Miller; Amy S Ruppert; Sydney Fobare; Timothy L Chen; Chaomei Liu; Amy Lehman; James S Blachly; Xiaoli Zhang; David M Lucas; Michael R Grever; Martin S Tallman; Ian W Flinn; Laura Z Rassenti; Thomas J Kipps; Deepa Sampath; Kevin R Coombes; Erin K Hertlein
Journal:  Oncotarget       Date:  2017-04-18

5.  The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia.

Authors:  Daphne Guinn; Amy Lehman; Catherine Fabian; Lianbo Yu; Kami Maddocks; Leslie A Andritsos; Jeffrey A Jones; Joseph M Flynn; Samantha M Jaglowski; Jennifer A Woyach; John C Byrd; Amy J Johnson
Journal:  Cancer Med       Date:  2017-03-15       Impact factor: 4.452

Review 6.  Prognostic and Clinicopathological Significance of MiR-155 in Hematologic Malignancies: A Systematic Review and Meta-analysis.

Authors:  Lu Tang; Yi-Zhong Peng; Cheng-Gong Li; Hui-Wen Jiang; Heng Mei; Yu Hu
Journal:  J Cancer       Date:  2019-01-01       Impact factor: 4.207

7.  Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia.

Authors:  David J Allsup; James M Allan; Wei-Yu Lin; Sarah E Fordham; Nicola Sunter; Claire Elstob; Thahira Rahman; Elaine Willmore; Colin Shepherd; Gordon Strathdee; Tryfonia Mainou-Fowler; Rachel Piddock; Hannah Mearns; Timothy Barrow; Richard S Houlston; Helen Marr; Jonathan Wallis; Geoffrey Summerfield; Scott Marshall; Andrew Pettitt; Christopher Pepper; Christopher Fegan; Francesco Forconi; Martin J S Dyer; Sandrine Jayne; April Sellors; Anna Schuh; Pauline Robbe; David Oscier; James Bailey; Syed Rais; Alison Bentley; Lynn Cawkwell; Paul Evans; Peter Hillmen; Guy Pratt
Journal:  Nat Commun       Date:  2021-01-28       Impact factor: 14.919

Review 8.  miR-155 as a Biomarker in B-Cell Malignancies.

Authors:  Hanne Due; Pernille Svendsen; Julie Støve Bødker; Alexander Schmitz; Martin Bøgsted; Hans Erik Johnsen; Tarec Christoffer El-Galaly; Anne Stidsholt Roug; Karen Dybkær
Journal:  Biomed Res Int       Date:  2016-05-16       Impact factor: 3.411

9.  Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.

Authors:  Laura Ondrisova; Marek Mraz
Journal:  Front Oncol       Date:  2020-10-26       Impact factor: 6.244

10.  miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.

Authors:  Sonali Sharma; Gabriela Mladonicka Pavlasova; Vaclav Seda; Katerina Amruz Cerna; Eva Vojackova; Daniel Filip; Laura Ondrisova; Veronika Sandova; Lenka Kostalova; Pedro F Zeni; Marek Borsky; Jan Oppelt; Kvetoslava Liskova; Leos Kren; Andrea Janikova; Sarka Pospisilova; Stacey M Fernandes; Medhat Shehata; Laura Z Rassenti; Ulrich Jaeger; Michael Doubek; Matthew S Davids; Jennifer R Brown; Jiri Mayer; Thomas J Kipps; Marek Mraz
Journal:  Blood       Date:  2021-05-06       Impact factor: 22.113
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.